Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10740084 | 0.79 | HIF1A (0.47) | MEN1KMT2ACYP2C19CYP3A4CYP2D6 | |
| Iodide SCHEMBL387026 | 0.79 | HIF1A (0.38) | MEN1KMT2ACYP2C19CYP2D6HIF1A | |
| SCHEMBL12382346 | 0.70 | MEN1 (0.47) | MEN1KMT2ACYP2C19CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9027797 | 0.69 | PDE4A (0.37) | HIF1AMAPTSNCACYP2C9LMNA | |
| Hydrochloric Acid SCHEMBL18110366 | 0.69 | HIF1A (0.39) | KMT2ACYP2C19CYP2D6HIF1AALDH1A1 | |
| SCHEMBL11447465 | 0.69 | MEN1 (0.51) | MEN1KMT2ACYP2C19CYP3A4CYP2D6 | |
| Water SCHEMBL28190270 | 0.68 | MEN1 (0.46) | MEN1KMT2ACYP2C19CYP3A4CYP2D6 | |
| SCHEMBL10413301 | 0.68 | CYP2C19 (0.54) | MEN1KMT2ACYP2C19CYP3A4CYP2D6 | |
| SCHEMBL10103709 | 0.68 | MEN1 (0.44) | MEN1KMT2ACYP2C19CYP3A4CYP2D6 | |
| SCHEMBL15762471 | 0.68 | MEN1 (0.50) | MEN1KMT2ACYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-7910617-B2 | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound | SANKYO COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| EP-1471054-B1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-7547790-B2 | Optically active 4,4-di-substituted oxazolidine derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20070191468-A1 | Amino alcohol compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1806344-A1 | OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1733724-A1 | AMINO ALCOHOL COMPOUND | Sankyo Company, Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | SANKYO COMPANY, LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | PHOSPHO1, CD4, FCGRT | MEN1 1065/4885KMT2A 3736/4885CYP2C19 796/4885 |
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | CBR3, C9, COX6C | MEN1 1770/4885KMT2A 1201/4885CYP2C19 68/4885 |
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | MEN1 307/4885KMT2A 2185/4885CYP2C19 1899/4885 |
| US-20070105933-A1 | Amino alcohol compounds | ADH1C, C9, SSB | MEN1 1067/4885KMT2A 2919/4885CYP2C19 1594/4885 |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | MEN1 1225/4885KMT2A 3339/4885CYP2C19 2615/4885 |
| US-20070191468-A1 | Amino alcohol compound | ADH1A, ADH1C, BCAT1 | MEN1 3109/4885KMT2A 400/4885CYP2C19 49/4885 |
| US-20100035842-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | PHOSPHO1, ADH1C, ADH1A | MEN1 940/4885KMT2A 1437/4885CYP2C19 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.